Onyx Snubbing Amgen Paves Way for 89% Deal Premium

Onyx Snubbing Amgen Paves Way for 89% Deal Premium

Onyx Pharmaceuticals via Bloomberg

Onyx reported $362 million of revenue in 2012, with 80 percent coming from two drugs it sells in partnership with Leverkusen, Germany-based Bayer - Nexavar for liver and kidney cancer, and Stivarga for stomach cancer.